Tebrazid

(Pyrazinamide)

Phase 3Small molecule

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Pyrazinamide is used to treat tuberculosis (TB), a serious lung infection. It works by killing the bacteria that cause TB and is typically used as part of a combination treatment with other TB medications.[1] Tebrazid is currently being investigated across 8 indications[3], with its most advanced program in Phase 3.[1]

Tebrazid is one of 198 small molecule programs targeting Mycobacterium infection. It is currently in Phase 3.

Indications

Total Trials

Active Trials

197

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mycobacterium InfectionUnknown

Multidrug-Resistant TuberculosisActive, not recruiting

Pulmonary TuberculosisRecruiting

ImmunodeficiencyActive, not recruiting

OsteomyelitisActive, not recruiting

HIVTerminated

TuberculosisUnknown

MeningitisActive, not recruiting

Mycobacterium InfectionPreclinical

Unknown

Multidrug-Resistant TuberculosisPhase 3

Active, not recruiting

Pulmonary TuberculosisPhase 2

Recruiting

ImmunodeficiencyPhase 2

Active, not recruiting

OsteomyelitisPhase 1

Active, not recruiting

HIVPhase 2

Terminated

TuberculosisPreclinical

Unknown

MeningitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

297 competitors in Tuberculosis

#DrugCompanyPhaseTrials

Rifadin

Sanofi

Phase 3

16 2

Avelox

Bayer

Phase 3

11 3

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

22 4

Onbrez

Novartis

Phase 3

1 5

Selenium

SSWOG Cancer Research Network

Phase 3

—6

Bacillus Calmette-Guerin

AstraZeneca

Phase 3

1 7

Contezolid

BBin Cao

Phase 3

2 8

Rifapentine and Moxifloxacin

CCenters for Disease Control and Prevention

Phase 3

3 9

Tivicay

GSK

Preclinical

4 10

Cabenuva

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Pulmonary Tuberculosis

NCT04485156

Phase 3Active, not recruiting

Tuberculosis

NCT06081361

Q1 2027

Phase 2Active, not recruiting

Drug

NCT05556746

Q3 2027

Phase 3Recruiting

Children

NCT06253715

Phase 2Recruiting

ESS

NCT06114628

Phase 2Recruiting

Pulmonary Tuberculosis

NCT06192160

Clinical

Trials by Indication[1]

Tuberculosis22 trials

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

Completed·UUniversity College, London·Phase 2/3·NCT03474198·675 enrolled

Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

Not yet recruiting·SShandong University·Phase 2·NCT06917495·300 enrolled

The Treatment of Tuberculosis in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001033·650 enrolled

Show 19 more trials

The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis

Unknown status·—·Phase 4·NCT02477852·400 enrolled

The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

Completed·IIUATLD, Inc·Phase 3·NCT02409290·588 enrolled

Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT04504851·154 enrolled

Tuberculosis Treatment Shortening Trial

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00130247·394 enrolled

Assessing PA-824 for Tuberculosis (the APT Trial)

Completed·JJohns Hopkins University·Phase 2·NCT02256696·157 enrolled

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00004736·44 enrolled

Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers

Completed·NNational University Hospital, Singapore·Phase 1·NCT02602509·18 enrolled

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Active, not recruiting·—·Phase 3·NCT06081361·186 enrolled

Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide

Suspended·UUniversity Hospital, Linkoeping·Phase 2·NCT04694586·40 enrolled

Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment

Not yet recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT05454345·620 enrolled

Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

Terminated·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01601626·71 enrolled

Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT07129629·45 enrolled

Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care

Completed·WWits Health Consortium (Pty) Ltd·Phase 3·NCT04062201·402 enrolled

A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00317330·6,400 enrolled

Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers

Completed·NNational University Hospital, Singapore·Phase 1·NCT02700347·12 enrolled

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Completed·CCenters for Disease Control and Prevention·Phase 3·NCT02563327·53 enrolled

Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00816426·19 enrolled

An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

Completed·UUniversity of Cape Town·Phase 2/3·NCT02454205·154 enrolled

Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000950·50 enrolled

Pulmonary Tuberculosis13 trials

A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis

Completed·GGlobal Alliance for TB Drug Development·Phase 2·NCT04179500·26 enrolled

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Active, not recruiting·CCenters for Disease Control and Prevention·Phase 2/3·NCT05766267·288 enrolled

Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)

Not yet recruiting·SSeoul National University Hospital·Phase 3·NCT04485156·926 enrolled

Show 10 more trials

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)

Completed·GGlobal Alliance for TB Drug Development·Phase 2·NCT01215851·85 enrolled

Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients

Unknown status·TTuberculosis Research Centre, India··NCT05047055·550 enrolled

A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis

Completed·SSt George's, University of London·Phase 3·NCT02581527·672 enrolled

Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia

Completed·UUniversity of Giessen·N/A·NCT02554318·147 enrolled

Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)

Completed·GGlobal Alliance for TB Drug Development·Phase 2·NCT01498419·207 enrolled

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)

Completed·GGlobal Alliance for TB Drug Development·Phase 2·NCT01691534·105 enrolled

A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.

Completed·GGlobal Alliance for TB Drug Development·Phase 2·NCT02193776·240 enrolled

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000796·525 enrolled

Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

Unknown status·—·Phase 4·NCT02901288·3,900 enrolled

A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06192160·315 enrolled

Drug3 trials

Evaluating Newly Approved Drugs for Multidrug-resistant TB

Completed·MMédecins Sans Frontières, France·Phase 3·NCT02754765·754 enrolled

PK Study of Anti-TB Drugs

Completed·UUniversity of Oxford·Phase 1·NCT02457208·61 enrolled

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

Active, not recruiting·—·Phase 2·NCT05556746·94 enrolled

Immunodeficiency3 trials

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000636·2,000 enrolled

Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)

Completed·UUniversity of Massachusetts, Worcester·Phase 2·NCT04930744·112 enrolled

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000638·2,000 enrolled

Treatment3 trials

Shortening Treatment by Advancing Novel Drugs

Completed·GGlobal Alliance for TB Drug Development·Phase 3·NCT02342886·284 enrolled

Treatment Shortening of MDR-TB Using Existing and New Drugs

Completed·SSeoul National University Hospital·Phase 2·NCT02619994·214 enrolled

Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

Completed·HHuashan Hospital·N/A·NCT04717908·89 enrolled

16 more indications

Efficacy2 trials

Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin

Withdrawn·—·Phase 3·NCT02975570

Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

Completed·GGlobal Alliance for TB Drug Development·Phase 2/3·NCT03338621·455 enrolled

Adult1 trial

Intensified Short Course Regimen for TBM in Adults

Not yet recruiting·IIndian Council of Medical Research·Phase 3·NCT05917340·372 enrolled

Meropenem1 trial

Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB

Completed·TTASK Applied Science·Phase 2·NCT04629378·22 enrolled

Children1 trial

Shortened Regimen for Drug-susceptible TB in Children

Recruiting·JJohns Hopkins University·Phase 3·NCT06253715·860 enrolled

TIA1 trial

Essentiality of INH in TB Therapy

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01589497·69 enrolled

Pulmonary TB1 trial

Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design

Completed·MMichael Hoelscher·Phase 2·NCT01785186·365 enrolled

Recruiting·UUniversity College, London·Phase 2·NCT06114628·2,500 enrolled

Elderly1 trial

Ultra-Short Regimen for Elderly DS-TB

Not yet recruiting·SShenzhen Third People's Hospital·Phase 3·NCT07076225·300 enrolled

Treatment Duration1 trial

Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

Not yet recruiting·UUniversity College, London·Phase 3·NCT07163143·784 enrolled

Trial1 trial

A PAN-USR TB Multi-Center Trial

Recruiting·SShenzhen Third People's Hospital·Phase 3·NCT06905522·610 enrolled

Resistance1 trial

TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance

Completed·CCenters for Disease Control and Prevention·N/A·NCT00023374·98 enrolled

NAC1 trial

PanACEA - STEP2C -01

Recruiting·MMichael Hoelscher·Phase 2·NCT05807399·390 enrolled

Multidrug-Resistant Tuberculosis1 trial

A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

Unknown status·—·Phase 4·NCT05306223·212 enrolled

HIV1 trial

A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04311502·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 61 trial records for Pyrazinamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pyrazinamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pyrazinamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Fatty Acid Synthase Inhibitor; 70s Ribosome Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Tebrazid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Trials by Indication[1]

Tuberculosis22 trials

Pulmonary Tuberculosis13 trials

Drug3 trials

Immunodeficiency3 trials

Treatment3 trials

Efficacy2 trials

Adult1 trial

Meropenem1 trial

Children1 trial

TIA1 trial

Pulmonary TB1 trial

Pregnancy1 trial

Meningitis1 trial

ESS1 trial

Elderly1 trial

Treatment Duration1 trial

Trial1 trial

Resistance1 trial

NAC1 trial

Multidrug-Resistant Tuberculosis1 trial

HIV1 trial

References

Drug Info

Quick Facts

Related News